FTSE Mondo Visione Exchanges Index:
News Centre
.jpg)
-
ESMA Publishes The Results Of The Annual Transparency Calculations For Equity And Equity-Like Instruments
Date 28/02/2025
The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, has today published the results of the annual transparency calculations for equity and equity-like instruments, which will apply from 7 April 2025.
-
FSB Call For Papers: 2025 Annual Meeting Of The Central Bank Research Association (CEBRA)
Date 28/02/2025
The FSB invites academic paper submissions for a session on ‘The Impact of Extreme Weather Events on the Financial System’ at the 2025 Annual Meeting of CEBRA.
-
MNI Indicators: Chicago Business Barometer™ - Increases To 45.5 In February
Date 28/02/2025
February 2025 Report
- The Chicago Business Barometer™, produced with MNI increased 6.0 points to 45.5 in February. This is the second consecutive monthly gain, taking the reading to the highest level since June 2024, though it remains in contractionary territory for the fifteenth consecutive month.
- The rise was driven by increases in four out of five subcomponents: Production, New Orders, Supplier Deliveries and Order Backlogs, whilst Employment fell.
- Production expanded 7.6 points. This is the second successive monthly increase taking the index to its highest level seen since June 2024.
-
Response To Staff Statement On Meme Coins: What Does It Meme? SEC Commissioner Caroline A. Crenshaw
Date 28/02/2025
The purpose of written guidance from SEC staff is to promote understanding of, and compliance with, the federal securities laws. Today’s guidance from the Division of Corporation Finance turns that concept on its head. It advances an incomplete, unsupported view of the law to suggest that an entire product category is outside the bounds of SEC jurisdiction.
-
CME Group To Launch Solana (SOL) Futures On March 17
Date 28/02/2025
CME Group, the world's leading derivatives marketplace, today announced plans to launch Solana (SOL) futures on March 17, pending regulatory review. Market participants will have the choice to trade both a micro-sized contract (25 SOL) and a larger-sized contract (500 SOL).
-
Statement By SEC Commissioner Caroline A. Crenshaw: Crypto 2.0: Regulatory Whiplash
Date 28/02/2025
[1]Today the Commission moved the Court to dismiss its enforcement action against Coinbase, a crypto trading platform. This reverse-course midstream – coupled with recent high-profile stays of other litigations – is not only unprecedented, it ignores 80 years of well-established law. We say we are dismissing the action because of future recommendations that may be made by the “crypto task force dedicated to helping the Commission develop the regulatory framework for crypto assets.”[2] But, whatever the law may be tomorrow, market participants should not be able to avoid the law as it stands today.
-
McKay Brothers Launches Fastest Connectivity Between Tokyo And Europe
Date 28/02/2025
- New ultra-low latency service connects crypto exchange clouds in Tokyo with those in London and Dublin
-
Finansinspektionen: Capital Requirements For Swedish Banks As Of Q4 2024
Date 28/02/2025
Finansinspektionen publishes the capital requirements of the largest Swedish banks and credit institutions that belong to supervisory categories 1 and 2 as of the end of Q4 2024.
-
Malawi Stock Exchange Weekly Summary Report 28 February 2025
Date 28/02/2025
Click here to download Malawi Stock Exchange's weekly summary report.
-
Trump’s NIH Funding Cuts And Freezes Raise Concerns Over US Biotech Drug Development And Innovation, Reveals GlobalData
Date 28/02/2025
The US President Donald Trump began his second term with a series of directives targeting the US National Institutes of Health (NIH), creating uncertainty around NIH grant funding for biopharmaceutical drug development. With over $1.4 billion in NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants involving innovator drugs awarded between 2020 and 2024, the funding cuts and freezes could hamper biopharmaceutical innovation and limit patient access to drugs, reveals GlobalData, a leading data and analytics company.
